NEUROBLASTOMA

This early-stage study tests a new drug called LY3295668 erbumine in children whose neuroblastoma has come back or not responded to treatment. The main goal is to see if the drug is safe and to find the best dose. About 71 participants will take the drug alone or with other medic…

This early-phase study tests a new treatment for children and young adults (up to age 26) with solid tumors that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack a protein c…

This study tests whether adding two chemotherapy drugs (irinotecan and temozolomide) to the standard immunotherapy regimen (dinutuximab, GM-CSF, and isotretinoin) can safely prevent high-risk neuroblastoma from returning after intensive initial therapy. About 41 children and youn…

This study tests a combination of two drugs—an antibody called Hu3F8 and a growth factor called GM-CSF—in children with high-risk neuroblastoma that has come back or not responded to standard therapy. The goal is to find a safe dose and see how well the body tolerates the treatme…

This early-phase trial tests a new combination therapy for children with neuroblastoma that has come back or not responded to treatment. It uses the child's own natural killer (NK) cells, grown in a lab, along with the drug dinutuximab, and sometimes lenalidomide, to try to contr…

This early-stage study tests a flavored, drinkable chemotherapy called VAL-413 (Orotecan) for children and young adults (ages 1-30) whose solid tumors have come back. The drug is given by mouth along with another chemo, temozolomide, for 5 days. The main goal is to find the safes…

This early-phase study tests a new combination of three drugs (radioactive therapy, an immunotherapy, and a checkpoint inhibitor) in children whose neuroblastoma has come back or is hard to treat. The main goal is to see if the combination is safe and tolerable. About 44 children…

This early-phase study tests an experimental drug called CLR 131 in children, adolescents, and young adults (ages up to 30) with certain cancers that have come back or not responded to standard treatments. The cancers include solid tumors (like neuroblastoma and sarcomas), lympho…

This study tests whether using the tumor's biology and how it responds to treatment can guide therapy for children with non-high-risk neuroblastoma. Some children may only need monitoring instead of immediate treatment, which could avoid unnecessary side effects. The trial enroll…

This early-phase study tests a new treatment for advanced osteosarcoma and neuroblastoma that has not responded to standard therapies. The approach uses a patient's own immune cells (T cells) that are genetically modified to recognize and attack cancer cells carrying a protein ca…

This early-phase study tests a personalized cell therapy for children and young adults (ages 1–30) whose solid tumors have come back or not responded to standard treatment. Researchers take a patient's own immune T cells, modify them to recognize and attack cancer cells that carr…

This early-stage trial tests a personalized treatment for children with recurrent neuroblastoma or a newly diagnosed brainstem tumor called DIPG. The approach combines targeted drugs with the child's own immune cells and stem cells, all customized to their tumor. The main goal is…

This early-phase trial tests a new treatment called GD2 CAR T cells in 12 children and teens (ages 1-16) with neuroblastoma that has come back or not responded to standard therapy. The treatment involves taking a patient's own immune cells, modifying them in a lab to better recog…

This early-phase study tests a three-drug combination (sorafenib, cyclophosphamide, and topotecan) in children and young adults with neuroblastoma that has come back or not responded to treatment. The main goal is to find the safest dose of sorafenib when given with the other two…

This early-phase study tests a new gene therapy for children with neuroblastoma that has come back or not responded to treatment. The therapy uses the patient's own immune cells (T cells) that are modified in the lab to recognize and attack neuroblastoma cells. The study aims to …

This study tested whether a fecal microbiota transplant (FMT) could improve standard treatment for neuroblastoma by fixing an imbalance in gut bacteria. Only one child with neuroblastoma and a specific gut bacteria gap was eligible. The goal was to see if correcting the microbiom…

This study looks at whether a special PET scan using a natural amino acid called methionine can help doctors see tumors in children and young adults with cancer. About 500 participants will get the scan to check if it can find tumors at diagnosis and tell the difference between a…

This study tests a new radioactive tracer called 18F-DA for PET scans to see if it can find neuroblastoma and pheochromocytoma tumors more clearly than the current tracer. About 20 children and adults with known or suspected tumors will receive the tracer and be monitored for sid…

This study tests whether a special PET/CT scan using a radioactive tracer called 68Ga-DOTATATE can better detect neuroendocrine tumors (like neuroblastoma) in children and young adults up to age 30. The scan is compared to the standard MIBG scan to see which one more clearly show…

This study tests whether giving the drug dinutuximab over 4 hours or less is safe and doable for children with high-risk neuroblastoma. Currently, the infusion takes 10-20 hours and requires a hospital stay. If successful, this faster method could allow treatment in an outpatient…

This study tests a radioactive antibody called 124I-Hu3F8 to see how it moves through the body and attaches to tumors in people with melanoma, neuroblastoma, or sarcoma. Seven participants received the antibody followed by PET/CT scans at several time points. The goal is to under…

This study looks for brand-new gene changes that appear in a child but not in their parents, which might raise the risk of certain cancers. Researchers will compare DNA from cancer patients and their healthy parents to spot these changes. The goal is to better understand cancer r…

This study looks at tumor samples from children and young adults with neuroblastoma that has come back or not responded to treatment. The goal is to find specific genetic changes or immune system markers that could be targeted with future therapies. By understanding these markers…